The Heartland Institute: Free Market Solutions

PolicyBot

PolicyBot is a search engine and database containing more than 24,000 studies and commentaries from more than 350 think tanks and advocacy groups. It’s free, fast, and comprehensive.

If you are conducting research on a particular topic, click on the plus (+) sign next to the topic in the list in the left-hand column of this page, then click on a subtopic. Titles, authors, publication date, reviews, and links to complete text will display for the 10 most-recent documents addressing that subtopic. Click on 2, 3, 4, etc. to see more documents.

If you are looking for an essay or report from a particular author or publisher, enter that information in the appropriate boxes below and then hit “search.” The search boxes can also be used to search by topic and subtopic. Problems or questions? Send an email to think@heartland.org.

If you come across what appears to be a “missing” or “empty” PolicyBot document, please let us know! Email us the URL or title of the document you’re trying to find, and we’ll get it fixed for you within minutes.

Search

Criteria

Keyword:
Author:
Publisher:
Added Since:
Document Number:
Topic:
Subtopic:

Results

Sort By: Date

19 article(s) found. Displaying article(s) 1 - 10.

1 2 ››

Dr. Richard Dolinar

Health Care News / The Heartland Institute / July 30, 2009

“Biologics,” or biologically produced drugs, constitute a huge and growing segment of the medical marketplace. They include insulin and many ... (read more)

‘Biosimilars’ Are ‘Biodifferent’

Dr. Richard Dolinar

The Heartland Institute / July 23, 2009

WASHINGTON -- Hidden in the congressional fireworks bursting over health-care overhaul and cap-and-trade is another highly contentious consumer issue ... (read more)

Protect The Promise of 'Biosimilar' Drugs

Dan Miller

News Release / The Heartland Institute / June 22, 2009

Congress is exploring legislation that would create a new drug-approval process in the Food and Drug Administration for what are called “biosimilars,” ... (read more)

Safety First: A Legislator’s Brief on Biosimilars

Richard Dolinar, M.D.

Heartland Policy Brief / The Heartland Institute / June 18, 2009

Congress is currently exploring legislation that would create a new drug approval process in the U.S. Food and Drug Administration for what are called follow-on ... (read more)

Wyeth Decision Threatens 'Litigation Explosion'

Dan Miller

News Release / The Heartland Institute / January 27, 2009

The California Supreme Court last week refused to review a controversial Court of Appeal ruling that decreed the manufacturer of a "pioneer" drug ... (read more)

Foreign Counterfeit Drugs Pose Increasing Threat

Aricka Flowers

Health Care News / The Heartland Institute / January 01, 2009

A bust confiscating more than two million counterfeit medicines in a Brussels airport has sparked new concern over the safety of the prescription drug market, ... (read more)

In Re: Vioxx Products Liability Litigation

United States District Court Eastern District of Louisiana

United States District Court Eastern District of Louisiana / November 22, 2006

This multidistrict products liability litigation involves the prescription drug Vioxx, known generically as Rofecoxib. Merck & Co., Inc. (“Merck”), a New ... (read more)